| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/03/2005 | US20050049290 Benzimidazole derivatives and their use as gnrh antagonists |
| 03/03/2005 | US20050049283 Compounds that inhibit factor xa activity |
| 03/03/2005 | US20050049278 Anticarcinogenic agents; synthesis |
| 03/03/2005 | US20050049274 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one |
| 03/03/2005 | US20050049265 Use of inhibitors of i$g(k)b kinease for the treatment of cancer |
| 03/03/2005 | US20050049264 Suppressing growth of abnormal cells; gastric, brain, colon, pancreatic, lung, renal, ovarian and prostatic cancer |
| 03/03/2005 | US20050049263 Purine analogs having hsp90-inhibiting activity |
| 03/03/2005 | US20050049261 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives |
| 03/03/2005 | US20050049259 Viricides; for the prophylaxis and treatment of herpes viral infections |
| 03/03/2005 | US20050049258 Enzyme inhibitors for phosphodiesterase isozymes for treatment of asthma, chronic bronchitis and chronic obstructive pulmonary disease |
| 03/03/2005 | US20050049251 Inhibitors of p38 |
| 03/03/2005 | US20050049249 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors |
| 03/03/2005 | US20050049246 Such as [3-(2-Bromo-ethoxy)-phenyl]-[4-(3-cyclohexyl-5-methyl-isoxazol-4-yl)-pyrimidin-2-yl]-amine |
| 03/03/2005 | US20050049238 Heterocyclic retinoid compounds |
| 03/03/2005 | US20050049233 Transdermal administering of testosterone |
| 03/03/2005 | US20050049216 Immunostimulatory nucleic acid molecules |
| 03/03/2005 | US20050049215 contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulating interferon-alpha to treat viral infections; oligonucleotide linked to a biodegradable delivery complex |
| 03/03/2005 | US20050049212 Eating disorders, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea; drug screening; diagnosis and therapy; kits; regulates metabolism of triglycerides |
| 03/03/2005 | US20050049205 Product from rose hips e.g. 3- beta -D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO); arthritis and osteoarthritis |
| 03/03/2005 | US20050049202 For treating disorders associated with excessive cytokine release such as interleukin-1 (IL-1) for example infection, cancer, asthma, coronary restenosis, autoimmune disease, cirrhosis, entotoxemia, reperfusion injury and septic shock; lactone or lactam-benzoates or benzamides |
| 03/03/2005 | US20050049190 Cation conducting gabaa receptors and their use |
| 03/03/2005 | US20050048528 Using immunoglobulins and diagnostic and/or prognostic tool for detection and treatment of cell proliferative disorders; immunodiagnostics; immunotherapy |
| 03/03/2005 | US20050048488 Expression vector comprising nucleotide sequences coding excitatory amino acid transporter 2 (EAAT2) proteins for use in identifying modulator for treatment and preention of neurological or psychiatric disorder |
| 03/03/2005 | US20050048478 Preparing agents which prevent and/or treat viral diseases; immunotherapy; mimetics |
| 03/03/2005 | US20050048476 Expression vector comprising tumor necrosis factor fusion for use in identifying modulator for treatment of cell proliferaive disorders; antitumor agents |
| 03/03/2005 | US20050048471 Albumin derivatives with therapeutic functions |
| 03/03/2005 | US20050048467 Method and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin |
| 03/03/2005 | US20050048466 Recombinant virus comprising virus proliferating essential gene (VPEG) for use in the treatment of cell proliferative disorders; cancer therapeutics |
| 03/03/2005 | US20050048132 Use of hydrochloric acid in the preparation of a medicament for the treatment of tumour |
| 03/03/2005 | US20050048104 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 03/03/2005 | US20050048081 Immunogenic compositions comprising DAL/DAT double mutant, auxotrophic attenuated strains of listeria and their mehods of use |
| 03/03/2005 | US20050048079 Induction response in cells; joining to adenosine triphosphate binding domain; therapy for Aids; anticancer agents |
| 03/03/2005 | US20050048070 Mixture of polypeptides from cytokeratins; anticancer agnets; vaccines |
| 03/03/2005 | US20050048068 Major histocompatibility complex epitopes; immunotherapy ; induce immunology response |
| 03/03/2005 | US20050048064 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability |
| 03/03/2005 | US20050048061 Uses of mammalian cytokines and agonists; related reagents |
| 03/03/2005 | US20050048060 Immunoconjugates |
| 03/03/2005 | US20050048055 Use of CD40 engagement to alter T cell receptor usage |
| 03/03/2005 | US20050048054 Lymphocytes; methods |
| 03/03/2005 | US20050048053 Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications |
| 03/03/2005 | US20050048045 Regulation of urokinase receptor expression by phosphoglycerate kinase |
| 03/03/2005 | US20050048031 Defective recombinant adenoviruses expressing cytokines for antitumor treatment |
| 03/03/2005 | US20050047996 Calibration of colorectal cancer; gene expression profile; administering to human an antibody which binds to protein markers |
| 03/03/2005 | CA2537263A1 Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| 03/03/2005 | CA2536654A1 Anti-cancer vaccines |
| 03/03/2005 | CA2536492A1 Process for producing cytotoxic lymphocytes |
| 03/03/2005 | CA2536317A1 Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer |
| 03/03/2005 | CA2536313A1 Fused pyrimidine derivative and use thereof |
| 03/03/2005 | CA2536288A1 Cancer metastasis inhibitor |
| 03/03/2005 | CA2535581A1 Use of polypeptides of the cupredoxin family in cancer therapy |
| 03/03/2005 | CA2535350A1 Acetylene derivatives as inhibitors of histone deacetylase |
| 03/03/2005 | CA2533889A1 Mitotic kinesin inhibitors |
| 03/03/2005 | CA2533435A1 Mitotic kinesin inhibitors |
| 03/03/2005 | CA2533126A1 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| 03/03/2005 | CA2523658A1 Rnai agents for anti-sars coronavirus therapy |
| 03/03/2005 | CA2519337A1 Anti-cancer virus desensitization method |
| 03/02/2005 | EP1510519A1 Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives |
| 03/02/2005 | EP1510518A2 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
| 03/02/2005 | EP1510515A1 Phenylglycine derivatives as serine protease inhibitors |
| 03/02/2005 | EP1510221A1 Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr |
| 03/02/2005 | EP1510219A1 Method for identifying at least one Aminopeptidase-inhibitor |
| 03/02/2005 | EP1510215A1 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same |
| 03/02/2005 | EP1510211A1 Pharmaceutical composition comprising N-retinyl-N-retinylidene Ethanolamine (A2E), isoforms of A2E or derivatives thereof |
| 03/02/2005 | EP1510137A1 Pyruvate enriched onion extract |
| 03/02/2005 | EP1509772A2 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2) |
| 03/02/2005 | EP1509614A1 Map-kinase inhibitors as regulators of tumor-associated antigen expression |
| 03/02/2005 | EP1509543A2 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus |
| 03/02/2005 | EP1509541A2 Novel recombinant anticoagulant proteins |
| 03/02/2005 | EP1509539A2 Novel compositions and methods for cancer |
| 03/02/2005 | EP1509532A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 03/02/2005 | EP1509529A2 Esters in position 20 of camptothecins |
| 03/02/2005 | EP1509528A2 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 03/02/2005 | EP1509526A2 Imidazo(1,2-a)pyrazin-8-ylamines, method of making, and method of use thereof |
| 03/02/2005 | EP1509524A1 Xanthine phosphodiesterase v inhibitor polymorphs |
| 03/02/2005 | EP1509521A2 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases |
| 03/02/2005 | EP1509515A2 Substituted 4-aryl-4h-pyrrolo 2,3-h chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 03/02/2005 | EP1509507A2 Mitotic kinesin inhibitors |
| 03/02/2005 | EP1509506A1 Pyridazine derivatives |
| 03/02/2005 | EP1509498A1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same |
| 03/02/2005 | EP1509253A1 Chimeric cd154 |
| 03/02/2005 | EP1509251A2 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 03/02/2005 | EP1509246A2 Thermosensitive polymer carriers having a modifiable physical structure for biochemical analysis, diagnosis, and therapy |
| 03/02/2005 | EP1509237A2 Methods of treating angiogenesis, tumor growth, and metastasis |
| 03/02/2005 | EP1509235A1 Method for the protection of endothelial and epithelial cells during chemotherapy |
| 03/02/2005 | EP1509233A1 Liquid formulation of decitabine and use of the same |
| 03/02/2005 | EP1509230A2 Method of treating cancer using kinase inhibitors |
| 03/02/2005 | EP1509229A1 Compositions comprising hepoxilin analogs and their use in the treatment of cancer |
| 03/02/2005 | EP1509226A2 Small molecule inhibitors of her2 expression |
| 03/02/2005 | EP1509224A1 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia |
| 03/02/2005 | EP1509223A1 Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin |
| 03/02/2005 | EP1509202A1 Novel high viscosity embolizing compositions comprising prepolymers |
| 03/02/2005 | EP1509188A2 Compounds active at the glucocorticoid receptor ii |
| 03/02/2005 | EP1509086A2 Htlv-i tax induced killing of p53 null cancer cells |
| 03/02/2005 | EP1421115B1 Soluble t cell receptor |
| 03/02/2005 | EP1244649B1 Cyclic amp-specific phosphodiesterase inhibitors |
| 03/02/2005 | EP1198475B1 Highly purified cytokine activating factor and methods of use |
| 03/02/2005 | EP1140017B1 Water-insoluble drug delivery system |
| 03/02/2005 | EP1137764B1 New medical use of gene and vector encoding a multisubstrate deoxyribonucleosidase |
| 03/02/2005 | EP1135105B1 Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder |
| 03/02/2005 | EP1129084B1 Thiazole derivatives as ppar gamma ligands |